Breaking News

NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein

JS201, developed by Junshi Biosciences, can simultaneously target PD-1 and TGF-β.

Author Image

By: Charlie Sternberg

Associate Editor

Shanghai Junshi Biosciences Co., Ltd. has announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (JS201) has been accepted by National Medical Products Administration (NMPA).   JS201 is a bifunctional fusion protein developed by Junshi using its proprietary technology that can simultaneously target PD-1 and TGF-β (transforming growth factor-β). It is the first product targeting PD-1/TGF-β approved for a clinical trial application in China. JS20...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters